And they're off... Melanoma March 2016 begins!
29 February 2016
Melanoma March 2016 has kicked off with a bang! More than 300 people marched in Rockingham, WA and Devonport, TAS this weekend. It was great to see the melanoma community uniting to remember those who they have lost to melanoma, support those fighting the disease, and to raise money to support melanoma research.
Clinton Heal from MelanomaWA said of the Rockingham march “There were also many people there living with melanoma, and their family and friends were there to get behind them and the balloon release ceremony was a great way to both remember and rally together for all those touched by melanoma. With a large increase in participation compared to the 2015 event, we are excited for even bigger and better things for the 2017 Rockingham Melanoma March!”.
MIA’s Merrin Lavender attended the Devonport Melanoma March, which was the first march ever held in Tasmania. She said it was a great success and guest speakers include the founder of Melanoma TAS and the Deputy Premier of Tasmania, Jeremy Rockliff.
Thank you to everyone who came out to support Melanoma March and to our dedicated volunteers who have been tirelessly organsing these events.
This weekend marks just the beginning of a 6-week campaign for Melanoma March where Australia will unite against melanoma in 24 locations around the country. Register or make a donation to support Melanoma March today.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.